Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEESBURG, Va.--(BUSINESS WIRE)--Stryker's navigation system offers surgeons a comprehensive planning and guidance solution for complex cranial procedures.

Stryker Announces Commercial Launch of Q Guidance System With Cranial Guidance Software

Stryker's (SYK) fully autonomous Ortho Q Guidance system offers smart and streamlined workflow, leading to enhanced procedural speed and efficiency.

Stryker (SYK) Launches Autonomous Guidance System for Surgeries

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

Ortho Q Guidance system with Ortho Guidance software offers state-of-the-art workflow KALAMAZOO, Michigan, USA, July 6, 2023 /PRNewswire/ -- Stryker (NYSE:SYK) announced the launch of its Ortho Q Guidance system, the only fully autonomous system in the industry, easily controlled by the surgeon from the sterile field. The system combines new optical tracking options via a redesigned, state-of-the-art camera with sophisticated algorithms of the newly launched Ortho Guidance software to deliver additional surgical planning and guidance capabilities  When used with Ortho Q, the Ortho Guidance software for Express Knee, Precision Knee and Versatile Hip serves as a planning and intraoperative guidance system that enhances procedural speed and efficiency through a smart, streamlined workflow.

Stryker launches industry's only fully autonomous guidance system

Chipotle

Visa

Chipotle Mexican Grill Inc. NYSE: CMG, Visa Inc. NYSE: V and Stryker Corp. NYSE: SYK may not, at first glance, seem like they have much in common. However, they're part of an elite group: All are S&P 500 components that are in buy range after recently breaking out of chart bases.

Bullish Action: Chipotle, Visa, Stryker Break Through Resistance

Stryker (SYK) Stock Hits 52-Week High: More Room to Grow?

Kalamazoo, Michigan, June 30, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for second quarter of fiscal year 2023 on Thursday, August 3, 2023.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter of fiscal year 2023, which ends on June 30, 2023.

Stryker to announce financial results for its second quarter of fiscal year 2023

Intuitive Surgical

Medtronic

The healthcare industry is facing pent-up demand for surgeries. Health insurers may struggle with some additional costs as a result.

Elective Surgeries Are On the Rise: 3 Stocks That Can Benefit From This Trend

Haleon PLC

Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?

HLN vs. SYK: Which Stock Should Value Investors Buy Now?

Stryker saw both net sales and profits grow in the first quarter. The medical device maker's dividend is easily covered by earnings.

This Healthcare Stock Is Sending More Cash to Its Shareholders: Should You Buy It?

Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Stryker (SYK) Moves 4.2% Higher: Will This Strength Last?

Investors with an interest in Medical - Products stocks have likely encountered both Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

HLN or SYK: Which Is the Better Value Stock Right Now?

There is more to the comparison, and in the sections below, we discuss why we believe that SYK will offer better returns than BAX in the next three years.

Should You Pick Stryker Stock Over BAX For Better Returns?

Stryker (SYK) reported earnings 30 days ago. What's next for the stock?

Why Is Stryker (SYK) Down 7.6% Since Last Earnings Report?

Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.

Stryker's (SYK) Q Guidance Successful in First Surgery

Here's Why You Should Retain Stryker (SYK) Stock for Now

LEESBURG, Va.--(BUSINESS WIRE)--Stryker launches Q Guidance System with Cranial Guidance Software, providing groundbreaking planning and guidance capabilities.

Surgeons Successfully Complete First Surgical Cases Using Stryker's Q Guidance System with Cranial Guidance Software

Vita Coco

Novo Nordisk

Shockwave Medical

Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.

3 Healthcare Trends to Ride for Longevity

Stryker and Medtronic are two of the biggest names in the medical device industry. Stryker is growing steadily, and its recent headwinds are clearing up.

Which Is the Safer Dividend Stock: Stryker or Medtronic?

Apple

Applied Materials

Amgen

Danaher

Home Depot

Jacobs Solutions Inc

Lowe's

Lam Research

NIKE

Paychex

Progressive

Raymond James

Warren Buffett held court again at Berkshire Hathaway's shareholder meeting. But his company could learn from some other S&P 500 companies.

16 Stocks Run Circles Around Warren Buffett Over The Long Haul

Boston Scientific

Insulet

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.

4 Medical Products Stocks to Capitalize on the Industry's Recovery

Thermo Fisher Scientific

Stalwarts are companies that have stood the test of time without trouble. Thermo Fisher's recent headwinds should have little impact on its long-term outlook.

Got $5,000? Buy These 2 Stalwart Stocks and Hold Them Forever

Baxter

Investors interested in stocks from the Medical - Products sector have probably already heard of Baxter International (BAX) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

BAX vs. SYK: Which Stock Should Value Investors Buy Now?

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves

KALAMAZOO, Michigan, USA, May 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms.

News for Stryker Stock (SYK)